P-tau181 is being surpassed by newer tau markers, particularly p-tau217, which shows significantly superior diagnostic accuracy for Alzheimer’s disease. In head-to-head comparisons, p-tau217 achieved an area under the curve (AUC) of 0.96 for detecting brain pathology, compared to p-tau181’s 0.76—a clinically meaningful gap that translates to fewer missed diagnoses and false positives. Beyond sheer accuracy, p-tau217 can differentiate between all four levels of Alzheimer’s neuropathological change (none, low, intermediate, and high), whereas p-tau181 can only distinguish between intermediate and high severity, making it less useful for staging early disease.
P-tau181 was the first plasma tau marker to gain widespread research traction and validation, which is why it remains familiar to many physicians and researchers. However, the discovery of p-tau217 and p-tau231—both of which outperform p-tau181 in key ways—has fundamentally shifted the landscape. P-tau217 received FDA approval in May 2025 as part of the Lumipulse diagnostic platform, making it the first plasma phospho-tau test approved for clinical use to aid in Alzheimer’s diagnosis. P-tau181, while validated and still used in clinical trials and research settings, has not received FDA approval as a standalone diagnostic device, marking a decisive divergence in clinical utility.
Table of Contents
- What Do the Diagnostic Numbers Actually Tell Us?
- The Neuropathology Problem: Why Staging Matters More Than You Might Think
- The Timeline Question: Which Marker Appears First?
- From Lab to Clinical Practice: The FDA Approval Reality
- The Platform Paradox: Different Assays, Different Results
- Current Clinical Applications: Where P-Tau181 Still Has a Role
- Why P-Tau181 Hasn’t Disappeared Despite Being Surpassed
What Do the Diagnostic Numbers Actually Tell Us?
P-tau181 demonstrated solid diagnostic performance in validation studies, with a sensitivity of 85% and specificity of 77%, yielding an overall diagnostic accuracy of 81% and an AUC of 0.86. This means that in a typical memory clinic population, p-tau181 correctly identified Alzheimer’s pathology four out of five times and ruled it out correctly in about three out of four cognitively normal people. For many research applications and early clinical adopters, this was considered sufficient to move the needle on non-invasive biomarker testing. P-tau217’s superiority becomes concrete when you look at real clinical comparisons.
In memory clinic data, p-tau217 achieved an AUC of 0.90 with 81% sensitivity and 91% specificity, while p-tau181 in the same cohort showed an AUC of 0.85 with only 67% sensitivity and 91% specificity. Notice that p-tau217 retained both higher sensitivity and higher overall accuracy despite matching specificity—meaning it caught more true cases of Alzheimer’s without generating more false alarms. When detecting amyloid pathology specifically via plasma biomarkers, p-tau217’s AUC was 0.85 compared to p-tau181’s 0.75, a 10-point gap that becomes significant when considering thousands of patients screened for amyloid-lowering therapy eligibility. The broader picture across multiple research cohorts shows p-tau217 consistently achieving AUCs between 0.92 and 0.95, while p-tau181 ranged from 0.86 to 0.90. This consistency matters because it suggests p-tau217’s advantage holds across different populations, age groups, and geographic regions—not just in a single well-optimized trial.
The Neuropathology Problem: Why Staging Matters More Than You Might Think
One of the most underappreciated advantages of p-tau217 is its ability to stage Alzheimer’s pathology across the full disease spectrum. Alzheimer’s neuropathology progresses through four recognized stages: no pathology, low-level changes, intermediate changes, and advanced changes. P-tau217 could differentiate between all four levels in research cohorts, whereas both p-tau181 and p-tau231 only distinguished between intermediate and high pathology—missing the ability to identify the earliest stages of neuropathological change. This limitation of p-tau181 has real consequences.
A patient with mild cognitive impairment and only low-level pathological changes might benefit from different counseling, monitoring frequency, or lifestyle interventions than someone with advanced pathology. P-tau181 cannot make this distinction, meaning physicians using only p-tau181 data might miss opportunities for truly early intervention. The test tells you whether someone has Alzheimer’s but not reliably how advanced their pathology is—a critical gap when disease-modifying treatments are becoming available earlier in the disease course. Additionally, the inability to stage disease with p-tau181 means researchers conducting longitudinal studies must rely on other, more expensive methods like positron emission tomography (PET) or cerebrospinal fluid testing to track disease progression. This increases costs and patient burden, particularly in community settings and memory clinics with limited resources.
The Timeline Question: Which Marker Appears First?
The sequence in which different phospho-tau species become abnormal in the brain tells us something crucial about disease biology. P-tau231 emerges earliest in preclinical Alzheimer’s disease—appearing even before detectable amyloid pathology by PET imaging. Studies showed that p-tau231 reached abnormal levels when amyloid burden was still minimal, capturing pathological changes that would otherwise be missed by amyloid-centric biomarkers. P-tau217 appears after p-tau231 but shows a stronger correlation with longitudinal cognitive decline and more precise neuropathological staging. In practical terms, this means p-tau231 is the early warning canary in the coal mine, useful for identifying people at risk of developing symptomatic Alzheimer’s before they show cognitive decline.
P-tau217 becomes more informative once the disease is more advanced, excelling at diagnostic accuracy and staging severity. P-tau181, by contrast, rises later in the disease process and doesn’t capture the earliest preclinical window as effectively. This temporal hierarchy has research implications. Studies investigating preclinical Alzheimer’s—people with positive amyloid pathology but normal cognition—might use p-tau231 as a screening tool and p-tau217 for diagnosis and staging. P-tau181 serves a supporting role but isn’t optimal for either the earliest detection or the most sophisticated staging.
From Lab to Clinical Practice: The FDA Approval Reality
On May 16, 2025, the FDA approved the Lumipulse G pTau217/β-Amyloid 1–42 Plasma Ratio as the first in vitro diagnostic device for clinical use to aid in Alzheimer’s diagnosis. This wasn’t a surprise to the field—the device had been designated a Breakthrough Device by the FDA in April 2024, signaling expedited review. Two other platforms received similar designations: Quanterix’s Simoa technology (March 2024) and Roche’s Elecsys platform (April 2024). Beckman Coulter’s p-tau217/Aβ42 ratio earned Breakthrough designation in January 2025. P-tau181, despite being well-validated and widely used in research and clinical trials, has not received FDA approval as a standalone diagnostic device. This means laboratories can offer p-tau181 testing under their own Clinical Laboratory Improvement Amendments (CLIA) certification, but it carries different regulatory weight than an FDA-cleared device.
For physicians, this translates to a practical advantage for p-tau217: the test has been officially vetted by the FDA using standardized data packages, predefined clinical cutoffs, and manufacturer quality assurances. The Lumipulse platform itself deserves mention. It’s a fully automated system with optimized assay buffers that provides significant logistical advantages over manual immunoassays. Hospitals and large clinics can integrate it into existing laboratory workflows without substantial retooling. Quanterix Simoa and Meso Scale Discovery offer ultrasensitive immunoassays with superior and more uniform performance compared to earlier immunoassay methods. Mass spectrometry assays, while labor-intensive, perform uniformly well across all p-tau species and serve as reference standards in research.
The Platform Paradox: Different Assays, Different Results
A crucial caveat rarely discussed in patient-facing materials is that the same p-tau species can show different performance depending on the assay platform used. P-tau181 measured on one platform might yield slightly different diagnostic accuracy than p-tau181 on another platform. This is partially driven by differences in antibody pairing, calibration, and buffer chemistry. What this means practically: if you’re comparing results across clinics or considering getting a second opinion, knowing which platform was used matters. A patient tested with a Lumipulse p-tau217 assay has data that’s directly comparable to FDA-cleared reference standards and cutoff values.
A patient tested with p-tau181 on a research-grade platform might not have the same standardized interpretation. This is changing as more p-tau species move through FDA approval pipelines, but it’s an important reality check for anyone reviewing their own test results or comparing results from different centers. The silver lining is that recent advances in automated and ultrasensitive platforms have made these tests more accessible than earlier labor-intensive methods. Ten years ago, phospho-tau testing required specialized research laboratories. Today, major commercial platforms can run these assays in hospital and reference laboratories across the country. As more platforms achieve FDA clearance, standardization should improve and variation should decrease.
Current Clinical Applications: Where P-Tau181 Still Has a Role
P-tau181 and p-tau217 are used together in several concrete clinical scenarios. The first is distinguishing Alzheimer’s disease from normal cognition in people with cognitive symptoms—screening who truly has Alzheimer’s pathology versus normal aging or other causes of cognitive decline. The second application is identifying candidates for amyloid-lowering immunotherapies like aducanumab, lecanemab, and donanemab. These drugs work only if amyloid pathology is present, and p-tau181 (like p-tau217) can identify amyloid status with reasonable accuracy, reducing the need for PET scans.
Both markers are being evaluated as endpoints in clinical trials for disease-modifying therapies. Researchers use plasma biomarkers as trial outcome measures because they’re non-invasive, scalable across trial sites, and cheaper than PET imaging or repeated lumbar punctures. P-tau181 remains valuable in this research context, particularly in ongoing trials that began when p-tau181 was the state-of-the-art marker. Discontinuing p-tau181 measurements mid-trial would complicate data analysis and potentially invalidate interim findings, so many large trials continue measuring p-tau181 even as p-tau217 gains prominence.
Why P-Tau181 Hasn’t Disappeared Despite Being Surpassed
The gap between p-tau181’s validation and p-tau217’s superior performance doesn’t mean p-tau181 is obsolete. There are practical and historical reasons it remains in use. First, massive amounts of p-tau181 data already exist in research databases, longitudinal cohort studies, and biobanks. Alzheimer’s Disease Neuroimaging Initiative (ADNI), the Australian Imaging, Biomarkers and Lifestyle Study, and other major cohorts measured p-tau181 years ago.
Replacing that data with p-tau217 would erase valuable longitudinal information and cost millions in resources. Second, many clinical trials are mid-course, and switching biomarkers would require regulatory approval and data re-analysis. A phase 3 trial that enrolled 2,000 participants with p-tau181 baseline measurements can’t simply switch to p-tau217 without complications. The existing data still provides clinical value and regulatory documentation. P-tau181 will likely persist in clinical practice and research for several more years as the field transitions to p-tau217 and p-tau231, with hospitals and clinics gradually adopting the newer markers as platforms come online and reimbursement patterns stabilize.
- —
